Publications by authors named "Philip Arlen"

Claim this Profile
N
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, Philip M Arlen, Karen A Autio

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells.
Massimo Fantini, Kwong Y Tsang, Philip M Arlen

Expert Rev Vaccines· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide.
Shruti U Gandhy, Fatima H Karzai, Marijo Bilusic, Sheri McMahon, Lisa M Cordes, Philip M Arlen

Eur Urol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine Evaluation of Catchment Area Relevance through Text Mining.
Philip A Arlen, Joseph Chakko, Geoffrey DeGennaro, Erin Kobetz, Brandon Mahal

Crit Rev Oncog· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
Massimo Fantini, Philip Martin Arlen, Kwong Yok Tsang

Front Immunol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
Ravi A Madan, Marijo Bilusic, Mark N Stein, Renee N Donahue, Philip M Arlen

Oncologist· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
Christopher B Cole, Maria Pia Morelli, Massimo Fantini, Markku Miettinen, Patricia Fetsch, Philip M Arlen

J Exp Clin Cancer Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
Christopher B Cole, Maria Pia Morelli, Massimo Fantini, Markku Miettinen, Patricia Fetsch, Philip M Arlen

J Exp Clin Cancer Res· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial.
Brandon M Huffman, Atrayee Basu Mallick, Nora K Horick, Andrea Wang-Gillam, Peter Joel Hosein, Philip Arlen

JAMA Netw Open· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201.
Kwong Y Tsang, Massimo Fantini, Anjum Zaki, Sharon A Mavroukakis, Maria Pia Morelli, Philip M Arlen

Cancers (Basel)· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas.
Kwong Yok Tsang, Massimo Fantini, Sharon A Mavroukakis, Anjum Zaki, Christina M Annunziata, Philip M Arlen

Cancers (Basel)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
Ravi A Madan, Fatima H Karzai, Munjid Al Harthy, Daniel P Petrylak, Joseph W Kim, Philip M Arlen

BJU Int· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
Ravi A Madan, Fatima Karzai, Renee N Donahue, Munjid Al-Harthy, Marijo Bilusic, Philip M Arlen

J Immunother Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer.
Richard D Kim, Nilofer S Azad, Michael A Morse, Elizabeth Poplin, Amit Mahipal, Philip M Arlen

Clin Cancer Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer.
Kristen P Zeligs, Maria Pia Morelli, Justin M David, Monica Neuman, Lidia Hernandez, Philip M Arlen

Front Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale, discovery and clinical development of NEO-201.
Philip M Arlen, Maria Pia Morelli

Expert Opin Biol Ther· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells.
Massimo Fantini, Justin M David, Hing C Wong, Christina M Annunziata, Philip M Arlen

Cancer Biother Radiopharm· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas.
Massimo Fantini, Justin M David, Olga Saric, Alexander Dubeykovskiy, Yongzhi Cui, Philip M Arlen

Front Immunol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoantigens in the immuno-oncology space.
Philip M Arlen

Future Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma.
Andrea B Apolo, Fatima H Karzai, Jane B Trepel, Sylvia Alarcon, Sunmin Lee, Philip M Arlen

Clin Genitourin Cancer· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.
Ravi A Madan, Fatima H Karzai, Yang-Min Ning, Bamidele A Adesunloye, Xuan Huang, Philip M Arlen

BJU Int· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer.
Muhammad S Beg, Nilofer S Azad, Sandip P Patel, Jose Torrealba, Sharon Mavroukakis, Philip M Arlen

Cancer Chemother Pharmacol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.
Lauren V Wood, Antonio Fojo, Brenda D Roberson, Meghan S B Hughes, William Dahut, Philip M Arlen

Oncoimmunology· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.
Christopher R Heery, B Harpreet Singh, Myrna Rauckhorst, Jennifer L Marté, Renee N Donahue, Philip M Arlen

Cancer Immunol Res· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
Christopher R Heery, Nuhad K Ibrahim, Philip M Arlen, Mahsa Mohebtash, James L Murray

JAMA Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis